Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 13/20 | 0.89 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.89 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.89 |
| ▸ | MEN1 | O00255 | 1/20 | 0.89 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.89 |
| ▸ | MAPT | P10636 | 1/20 | 0.89 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.89 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.89 |
| ▸ | PPARG | P37231 | 8/20 | 0.76 |
| ▸ | FABP2 | P12104 | 2/20 | 0.76 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.76 |
| ▸ | PPARD | Q03181 | 3/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.57 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.57 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.57 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.57 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.57 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Clofibric Acid SCHEMBL102826 | 0.94 | PPARA (1.00) | PPARACYP1A2CYP3A4MEN1CYP2D6 | |
| Clofibric Acid SCHEMBL2227936 | 0.94 | PPARA (1.00) | PPARACYP1A2CYP3A4MEN1CYP2D6 | |
| Clofibric Acid SCHEMBL10634899 | 0.93 | PPARA (0.96) | PPARACYP1A2CYP3A4MEN1CYP2D6 | |
| Clofibric Acid SCHEMBL28722594 | 0.93 | PPARA (0.96) | PPARACYP1A2CYP3A4MEN1CYP2D6 | |
| Clofibric Acid SCHEMBL317991 | 0.93 | PPARA (0.96) | PPARACYP1A2CYP3A4MEN1CYP2D6 | |
| Clofibric Acid SCHEMBL11798397 | 0.93 | PPARA (0.96) | PPARACYP1A2CYP3A4MEN1CYP2D6 | |
| Clofibric Acid SCHEMBL11798234 | 0.93 | PPARA (0.96) | PPARACYP1A2CYP3A4MEN1CYP2D6 | |
| Clofibric Acid SCHEMBL28571877 | 0.93 | PPARA (0.96) | PPARACYP1A2CYP3A4MEN1CYP2D6 | |
| Clofibric Acid SCHEMBL11798560 | 0.91 | PPARA (0.93) | PPARACYP1A2CYP3A4MEN1CYP2D6 | |
| SCHEMBL11545612 | 0.91 | PPARA (0.71) | PPARACYP1A2CYP3A4MEN1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220409566-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-12-29 | — | — | US | disclosed |
| US-20220304957-A1 | ANTI-CANCER COMPOSITIONS AND METHODS OF USE | UNIV LOUISIANA STATE (US) | 2022-09-29 | — | — | US | disclosed |
| US-20220142961-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-05-12 | — | — | US | disclosed |
| US-11318111-B2 | CCL5 inhibitors | LAPKO INC (US) | 2022-05-03 | — | — | US | disclosed |
| US-20210196665-A1 | CCL5 Inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-07-01 | — | — | US | disclosed |
| US-10940132-B2 | CCL5 inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| WO-2020146876-A2 | ANTI-CANCER COMPOSITIONS AND METHODS OF USE | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2020-07-16 | — | — | WO | disclosed |
| US-20200138766-A1 | CCL5 INHIBITORS | LAPKO INC. DBA AFECTA PHARMACEUTICALS | 2020-05-07 | — | — | US | disclosed |
| US-5308830-A | Low dosage; nonphytotoxic to crops; pre- and postemergence | ROHM AND HAAS COMPANY (US) | 1994-05-03 | — | — | US | disclosed |
| US-5304531-A | Preemergent, postemergent, controls weed growth 2-chloro-4-trifluoromethyl-3' (1-(carboethoxy) ethoxycarbonyl)-4-nitrodiphenyl ether | BASF CORPORATION | 1994-04-19 | — | — | US | disclosed |
| US-4894479-A | CARBONYLOXYAMINO DERIVATIVES | ROHM AND HAAS COMPANY (US) | 1990-01-16 | — | — | US | disclosed |
| US-4863507-A | Herbicidal 4-trifluoromethyl-4-nitrodiphenyl ethers | ROHM AND HAAS COMPANY (US) | 1989-09-05 | — | — | US | disclosed |
| EP-0047972-B1 | ENHANCEMENT OF CARBOHYDRATE DEPOSITION IN PLANTS WITH SUBSTITUTED PHENOXYALKANOIC-ACID AND CYCLOHEXANE-DIONE DERIVATIVES | HOECHST AKTIENGESELLSCHAFT (DE) | 1985-10-30 | — | — | EP | disclosed |
| US-4386954-A | Herbicidal diphenyl ethers | ROHM AND HAAS COMPANY (US) | 1983-06-07 | — | — | US | disclosed |
| EP-0020052-A1 | Novel substituted nitrodiphenyl ethers, herbicidal compositions containing them, processes for the preparation thereof and the use thereof for combating weeds | ROHM AND HAAS COMPANY (US) | 1980-12-10 | — | — | EP | disclosed |
| US-4156011-A | TREATMENT OF CARDIOVASCULAR DISORDERS | SOCIETE ANONYME DITE: LABORATOIRE L. LAFON (FR) | 1979-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220142961-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | PPARA 806/4885CYP1A2 2919/4885CYP3A4 681/4885 |
| US-20200138766-A1 | CCL5 INHIBITORS | CCL5, CCL11, CCR5 | PPARA 806/4885CYP1A2 2919/4885CYP3A4 681/4885 |
| US-20210196665-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | PPARA 806/4885CYP1A2 2919/4885CYP3A4 681/4885 |
| US-10940132-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | PPARA 806/4885CYP1A2 2919/4885CYP3A4 681/4885 |
| US-11318111-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | PPARA 806/4885CYP1A2 2919/4885CYP3A4 681/4885 |
| US-20220304957-A1 | ANTI-CANCER COMPOSITIONS AND METHODS OF USE | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TP53, MCL1 | PPARA 1460/4885CYP1A2 3362/4885CYP3A4 3638/4885 |
| US-20220409566-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | PPARA 806/4885CYP1A2 2919/4885CYP3A4 681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.